Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today

These are historic days for the company, following its first FDA approval.The stock of biotech Arrowhead Pharmaceuticals (ARWR +23.34%) experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company's shares rose by more than 23%, thanks largely to its latest earnings release. A flying arrowThe previous day at market close, Arrowhead took the wraps off its full-year, fiscal 2025 results. The company's revenue for the period exceeded $829 million, primarily driven by an influx of lice ...